With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

Phase 2 trial is designed to evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a ...

KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access ...

As the approval date for Bristol Myers Squibb’s schizophrenia drug KarXT looms, a prodrug approach emerges to potentially ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. | Neurocrine Biosciences’ schizophrenia program pivot has ...

Japanese biopharma Nxera Pharma has secured $35m in milestone payments from Neurocrine Biosciences following positive Phase ...

Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.

Morgan Stanley analyst Terence Flynn has maintained their bearish stance on BMY stock, giving a Sell rating on September 3. Terence Flynn has ...